formerly mela sciences, strata skin sciences is a new company built by unconventional thinkers. a medical technology company that brings hope and help to the dermatology patient in all of us. it’s not just a device or a technology, it’s optimism for psoriasis, determination for improving patients’ lives, and advocacy for getting it right.
Company profile
Ticker
SSKN
Exchange
Website
CEO
Dolev Rafaeli
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ELECTRO OPTICAL SCIENCES INC /NY, MELA SCIENCES, INC. /NY
SEC CIK
Corporate docs
IRS number
133986004
SSKN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
27 Mar 24
8-K
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
27 Mar 24
8-K
STRATA Skin Sciences Announces Successful Amendment to Credit Agreement with MidCap Financial
26 Feb 24
8-K
Entry into a Material Definitive Agreement
21 Feb 24
8-K
STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference
8 Jan 24
8-K
STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
3 Jan 24
8-K
STRATA Skin Sciences Announces Expansion of Distribution Agreement with Kosmo Meditech
29 Dec 23
8-K
Departure of Directors or Certain Officers
15 Nov 23
8-K
STRATA Skin Sciences Reports Third Quarter 2023 Revenue
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
Transcripts
SSKN
Earnings call transcript
2023 Q4
27 Mar 24
SSKN
Earnings call transcript
2023 Q3
14 Nov 23
SSKN
Earnings call transcript
2023 Q2
9 Aug 23
SSKN
Earnings call transcript
2023 Q1
15 May 23
SSKN
Earnings call transcript
2022 Q4
31 Mar 23
SSKN
Earnings call transcript
2022 Q3
10 Nov 22
SSKN
Earnings call transcript
2022 Q2
10 Aug 22
SSKN
Earnings call transcript
2022 Q1
12 May 22
SSKN
Earnings call transcript
2021 Q4
21 Mar 22
SSKN
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.47 mm | 8.47 mm | 8.47 mm | 8.47 mm | 8.47 mm | 8.47 mm |
Cash burn (monthly) | 643.33 k | 29.17 k | 205.00 k | 419.08 k | 332.33 k | 169.17 k |
Cash used (since last report) | 3.84 mm | 174.25 k | 1.22 mm | 2.50 mm | 1.99 mm | 1.01 mm |
Cash remaining | 4.62 mm | 8.29 mm | 7.24 mm | 5.96 mm | 6.48 mm | 7.45 mm |
Runway (months of cash) | 7.2 | 284.3 | 35.3 | 14.2 | 19.5 | 44.1 |
Institutional ownership, Q3 2023
49.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 27 |
Opened positions | 4 |
Closed positions | 3 |
Increased positions | 3 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 6.30 bn |
Total shares | 17.38 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
22NW Fund | 5.37 mm | $3.12 mm |
22NW | 5.37 mm | $3.20 bn |
Nantahala Capital Management | 3.26 mm | $1.94 bn |
Renaissance Technologies | 1.08 mm | $642.00 k |
Vanguard | 858.20 k | $510.63 mm |
Essex Investment Management | 407.45 k | $242.43 mm |
Cannell Capital | 351.61 k | $209.00 k |
Geode Capital Management | 110.62 k | $65.85 mm |
Creative Planning | 100.01 k | $59.51 mm |
Perritt Capital Management | 100.00 k | $59.50 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.47 | 4,800 | 2.26 k | 20,000 |
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.46 | 300 | 138.00 | 15,200 |
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.45 | 562 | 252.90 | 14,900 |
1 Dec 23 | Shmuel Gov | SSKN Common Stock | Buy | Acquire P | No | No | 0.44 | 14,338 | 6.31 k | 14,338 |
21 Nov 23 | Christopher Lesovitz | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 337,500 | 168.75 k | 787,500 |
21 Nov 23 | Shmuel Gov | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.5 | 416,250 | 208.13 k | 971,250 |
16 Nov 23 | Samuel Rubinstein | Common Stock | Sell | Dispose S | No | No | 0.32 | 1,000 | 320.00 | 177,602 |
News
Strata Skin Sciences Q4 EPS $(0.04) Misses $(0.02) Estimate, Sales $8.69M Miss $10.01M Estimate
27 Mar 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
27 Mar 24
Recap: Strata Skin Sciences Q4 Earnings
27 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
27 Mar 24
Earnings Scheduled For March 27, 2024
27 Mar 24
Press releases
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings
27 Mar 24
STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage
7 Mar 24
STRATA Skin Sciences to Present Poster Showcasing Safety and Efficacy of TheraClear®X for Acne at Maui Derm 2024 Conference
8 Jan 24
STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
3 Jan 24